REFERENCES

1. World Health Organization. WHO Guillain-Barre Syndrome Fact Sheets. Oct

2016.
2. Michael TA. Guillain-Barre Syndrome. Medscape. 2018 Jan.
http://emedicine.medscape.com/article/315632-overview
3. Hughes RA, Cornblath DR; Guillain-Barr Syndrome. Lancet. 2005 Nov 5.
366(9497): 1653-66
4. Masdar Muid; Manifestasi Klinis dan Laboratoris Penderita Sindroma
Guillain-Barr di Ruang Perawatan Anak RSU Dr. Saiful Anwar Malang. Jurn
Ked Braw. 2005 Agust. XXI: 90-96
5. Roger PS, Michael JA, David AF; Clinical Neurology 7th ed. 2009. McGraw-
Hill
6. Mahinda Yogarajah. Crash Course Neurology 4th ed. 2013. Mosby Esevier.
7. Geleijns K, Emonts M, Laman JD, et al; Genetic polymorphisms of
macrophage-mediators in Guillain-Barr Syndrome. J Neuroimmunol. 207;
190:127-130.
8. Schwerer B; Antibodies against gangliosides: A Link Between Preceding
Infection and Immunopathogenesis of Guillain-Barr Syndrome. Microbes
Infect. 2002; 373-384.
9. Hadden RD, Karch H, Hartung H, et al. Preceding Infection, Immune Factors
and Outcome in Guillain-Barr Syndrome. Neurology. 2001; 56: 758-765.
10. Van Koningsveld R, Van Dorn PA, Schmitz PI, et al. Mild Forms of Guillain-
Barr Syndrome in an Epidemiologic Survey in The Netherlands. Neurology.
2000; 54: 620-625.
11. Malkki H. CNS Infections: Zika Virus Infection Could Trigger Guillain-Barr
Syndrome. Nat Rev Neurol. 2016; 12: 187.
12. Hiraga A, Mori M, Ogawara K, et al. Recovery Patterns and Long-term
Prognosis For Axonal Guillain-Barr Syndrome. J Neurol Neurosurg
Psychiatry. 2005; 76: 719-722.
13. Ropper AH. Unusual Clinical Variants and Sings in Guillain-Barr Syndrome.
Arch Neurol. 1968; 43: 1150-1152.
14. Ropper AH. The Guillain-Barr Syndrome. N Engl J Med. 1992; 326: 1130-
1136.
15. Poropatich KO, Walker CL, Black RE. Quantifiying The Association Between
Campylobacter Infections on Guillain-Barr Syndrome: A Systematic Review.
J Health Popul Nutr. 2010; 28: 545-552.
16. Fisher M. An Unusual Variant of Acute Idiopathic Polyneuritis (Syndrome of
Ophthalmoplegia,Ataxia, and Areflexia). N Engl J Med. 1956; 255: 57-65.
17. Hadden RD, Karch H, Hartung HP, et al. Preceding Infections, Immune Factors
and Outcome in Guillain-Barr Syndrome. Neurology. 2002; 59: 800-811.
18. US Food and Drug Administration. FDA and CDC issue alert on Minactra
Meningococcal Vaccine and Guillain-Barr Syndrome. Sept 2005.
19. Hahn AF. Guillain-Barr syndrome. Lancet. 1998;352:635-641.
20. Asbury AK, Arnason BG, Adams RD. The inflammatory lesion in idiopathic
polyneuritis. Its role in pathogenesis. Medicine (Baltimore). 1969;48:173-215.
21. Brown WF, Feasby TE. Conduction block and denervation in Guillain-Barr
polyneuropathy. Brain. 1984;107:219-239.
22. Strauss AJL, Seigel BC, Hsu KC. Immunofluorescent Demonstration of A
Mucle Binding Complement Fixing Serum Globulin Fraction in Myasthenia
Gravis. Proc Soc Exp Biol. 1960;105: 184.
23. Patric J,Lindstrom JM. Autoimmune Response to Acetylcholine Receptor.
Science. 1973; 180: 871.
24. Ropper AH, Maramou A. Mechanism of Pseudotumor in Guillain-Barr
Syndrome. Arch Neurol. 1984; 41: 259-261.
25. Hughes RA, Swan AV, Raphael JC, et al. Immunotherapy for Guillain-Barr
Syndrome: A Systematic Review. Brain. 2007; 130: 2245-2257.
26. Hughes RA, Swan AV, Van Doorn PA. Intravenous Immunoglobulin for
Guillain-Barr Syndrome.Cochrane Database Syst Rev. 2014; (9): CD002063.
27. Hughes RA, Wijdicks EF, Barohm R, et al. Practice Parameters:
Immunotherapy for Guillain-Barr Syndrome:Report of Quality Stavolors
Subcommittee of The American Academy of Neurology. Neurology. 2003; 61:
736-740.
28. Yu Z, Lennon VA. Mechanism of Intravenous Immunoglobulin Therapy in
Antibody-Mediated Autoimmune Disease. N Engl J Med. 1999; 340: 227-228.
29. Raphael JC, Chevret S, Hughes RA, et al. Plasma Exchange for Guillain-Barr
Syndrome. Cochrane Database Syst Rev. 2012; (7): CD001798.
30. McKhann GM, Griffin JW, Cornblath DR, et al. Plasmapheresis and Guillain-
Barr Syndrome: Analysis of Prognostic Factor and The Effect of
Plasmapheresis. Ann Neurol. 1988; 23: 347-353.
31. Hughes RA, WIjdicks EF, Benson E, et al. Supportive Care for PatientsWith
Guillain-Barr Syndrome. Arch Neurol. 2005; 62: 1194-1198.
32. Raphael JC, Chevret S, Harboun M, et al. Intravenous Immunoglobulin In
Patients with Guillain-Barr Syndrome and Contraindications to Plasma
Exchange: 3 days versus 6 days. J Neurol Neurosurg Psychiatry. 2001; 71: 235-
238.
33. Hadden RD, Hughes RA. Management of Inflammatory Neuropathies. J
Neurol Neurosurg Psychiatry. 2003; 74 (suppl 2): 119-124.
34. Hughes RA, Wijdicks EF, Benson E, et al. Supportive Care For Patients With
Guillain-Barr Syndrome. Arch Neurol. 2005; 62: 1194-1198.
35. Gracey DR, McMichan JC, Divertie MB, et al. Respiratory Failure in Guillain-
Barr Syndrome: A 6-years experience. Mayo Clinic Pro. 1982; 57: 742-746.
36. Fletcher DO, Lawn ND, Wolter TD, et al. Long-term Outcome in Patients with
Guillain-Barr Syndrome Requiring Mechanical Ventilation. Neurol. 2000; 54:
2311-2315.
37. Guillain-Barr Syndrome Study Group. Guillain-Barr Syndrome: An Italian
Multicentre Case-Control Study. Neurol Sci. 2000; 21: 229-234.